Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$30.93 -2.4%	$23.77	$14.86 ▼ $32.52	$1.23B	0.44	1.22 million shs	1.14 million shs
BAX Baxter International	$19.24 -0.7%	$17.93	$15.73 ▼ $32.04	$10.01B	0.64	6.35 million shs	5.04 million shs
DVA DaVita	$191.84 -0.2%	$172.18	$101.00 ▼ $202.69	$12.34B	0.91	818,988 shs	623,568 shs
DXCM DexCom	$76.62 +5.2%	$65.04	$54.11 ▼ $89.98	$28.11B	1.45	6.85 million shs	7.48 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	0.00%	+9.26%	+10.18%	+54.35%	+50.65%
BAX Baxter International	0.00%	+3.19%	+7.86%	+8.21%	-35.98%
DVA DaVita	0.00%	-0.97%	-3.08%	+25.90%	+39.39%
DXCM DexCom	0.00%	-1.19%	+20.21%	+5.99%	-15.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$30.93 -2.4%	$23.77	$14.86 ▼ $32.52	$1.23B	0.44	1.22 million shs	1.14 million shs
BAX Baxter International	$19.24 -0.7%	$17.93	$15.73 ▼ $32.04	$10.01B	0.64	6.35 million shs	5.04 million shs
DVA DaVita	$191.84 -0.2%	$172.18	$101.00 ▼ $202.69	$12.34B	0.91	818,988 shs	623,568 shs
DXCM DexCom	$76.62 +5.2%	$65.04	$54.11 ▼ $89.98	$28.11B	1.45	6.85 million shs	7.48 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	0.00%	+9.26%	+10.18%	+54.35%	+50.65%
BAX Baxter International	0.00%	+3.19%	+7.86%	+8.21%	-35.98%
DVA DaVita	0.00%	-0.97%	-3.08%	+25.90%	+39.39%
DXCM DexCom	0.00%	-1.19%	+20.21%	+5.99%	-15.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.22	Hold	$25.29	-18.25% Downside
BAX Baxter International	1.92	Reduce	$19.73	2.52% Upside
DVA DaVita	2.38	Hold	$199.17	3.82% Upside
DXCM DexCom	2.92	Moderate Buy	$83.04	8.38% Upside

Current Analyst Ratings Breakdown

Latest BAX, AMN, DVA, and DXCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/8/2026	DXCM DexCom	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$91.00
6/5/2026	DXCM DexCom	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$85.00 ➝ $90.00
6/1/2026	DXCM DexCom	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
5/28/2026	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$79.00 ➝ $84.00
5/28/2026	BAX Baxter International	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$19.00 ➝ $17.00
5/25/2026	BAX Baxter International	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/22/2026	AMN AMN Healthcare Services	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/20/2026	AMN AMN Healthcare Services	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/18/2026	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$100.00 ➝ $82.00
5/18/2026	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underweight	$67.00 ➝ $64.00
5/18/2026	DXCM DexCom	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $80.00

(Data available from 6/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.73B	0.44	$8.10 per share	3.82	$16.72 per share	1.85
BAX Baxter International	$11.24B	0.88	$5.64 per share	3.41	$11.87 per share	1.62
DVA DaVita	$13.64B	0.90	$21.68 per share	8.85	($5.29) per share	-36.27
DXCM DexCom	$4.66B	6.34	$2.91 per share	26.31	$7.04 per share	10.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$95.70M	-$0.87	N/A	24.74	0.73	-0.95%	18.01%	5.19%	8/6/2026 (Estimated)
BAX Baxter International	-$957M	-$2.13	N/A	9.77	3.12	-9.70%	16.15%	5.24%	7/30/2026 (Estimated)
DVA DaVita	$746.80M	$10.78	17.80	10.44	0.63	5.65%	-270.37%	4.87%	8/5/2026 (Estimated)
DXCM DexCom	$836.30M	$2.34	32.74	25.29	1.14	19.31%	33.33%	13.19%	7/29/2026 (Estimated)

Latest BAX, AMN, DVA, and DXCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	AMN AMN Healthcare Services	$1.60	$2.10	+$0.50	$1.59	$1.23 billion	$1.38 billion
5/5/2026	Q1 2026	DVA DaVita	$2.33	$2.87	+$0.54	$2.87	$3.36 billion	$3.42 billion
4/30/2026	Q1 2026	BAX Baxter International	$0.31	$0.36	+$0.05	-$0.03	$2.62 billion	$2.70 billion
4/30/2026	Q1 2026	DXCM DexCom	$0.47	$0.56	+$0.09	$0.51	$1.17 billion	$1.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
BAX Baxter International	$0.04	0.21%	-11.54%	N/A	N/A
DVA DaVita	N/A	N/A	N/A	N/A	N/A
DXCM DexCom	N/A	N/A	N/A	N/A	N/A

Latest BAX, AMN, DVA, and DXCM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	BAX Baxter International	quarterly	$0.01	0.21%	5/29/2026	5/29/2026	7/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.04	1.09	1.09
BAX Baxter International	1.43	1.85	1.23
DVA DaVita	N/A	1.42	1.37
DXCM DexCom	0.42	1.95	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
BAX Baxter International	90.19%
DVA DaVita	90.12%
DXCM DexCom	97.75%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	1.07%
BAX Baxter International	0.17%
DVA DaVita	1.50%
DXCM DexCom	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,664	38.79 million	38.37 million	Optionable
BAX Baxter International	37,500	516.47 million	515.59 million	Optionable
DVA DaVita	78,000	64.20 million	63.24 million	Optionable
DXCM DexCom	11,000	385.87 million	384.79 million	Optionable

BAX, AMN, DVA, and DXCM Headlines

Recent News About These Companies

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

2 hours ago | finance.yahoo.com

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

June 8 at 2:31 PM | benzinga.com

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

June 8 at 2:31 PM | zacks.com

DexCom jumps as new ADA trial data boosts optimism for broader CGM adoption

June 8 at 12:30 PM | quiverquant.comQ

Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $358,576.00 in Stock

June 8 at 4:23 AM | americanbankingnews.com

Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $364,052.43 in Stock

June 8 at 4:23 AM | americanbankingnews.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.30 Million Holdings in DexCom, Inc. $DXCM

June 8 at 3:48 AM | marketbeat.com

World Investment Advisors Buys 16,749 Shares of DexCom, Inc. $DXCM

June 7 at 7:22 AM | marketbeat.com

DexCom, Inc. $DXCM Position Boosted by ING Groep NV

June 7 at 6:40 AM | marketbeat.com

Los Angeles Capital Management LLC Raises Holdings in DexCom, Inc. $DXCM

June 7 at 6:39 AM | marketbeat.com

PBU The Pension Fund of Early Childhood & Youth Educators Invests $3.19 Million in DexCom, Inc. $DXCM

June 7 at 5:55 AM | marketbeat.com

Dexcom study highlights benefits of G7 CGM in non-insulin type 2 diabetes

June 6 at 5:53 PM | drugdeliverybusiness.comD

Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum

June 6 at 5:53 PM | finance.yahoo.com

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

June 6 at 5:53 PM | finance.yahoo.com

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

June 6 at 2:49 PM | reuters.com

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

June 6 at 2:45 PM | businesswire.com

DexCom (NASDAQ:DXCM) EVP Sells $358,576.00 in Stock

June 6 at 7:44 AM | insidertrades.com

WCG Wealth Advisors LLC Invests $2.04 Million in DexCom, Inc. $DXCM

June 6 at 7:05 AM | marketbeat.com

Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 4,912 Shares of Stock

June 5 at 5:13 PM | marketbeat.com

DexCom, Inc. $DXCM Holdings Decreased by Westfield Capital Management Co. LP

June 5 at 7:22 AM | marketbeat.com

Is DexCom Stock Underperforming the Dow?

June 5 at 6:50 AM | barchart.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BAX, AMN, DVA, and DXCM Company Descriptions

AMN Healthcare Services NYSE:AMN

$30.93 -0.76 (-2.40%)

Closing price 03:59 PM Eastern

Extended Trading

$30.96 +0.03 (+0.09%)

As of 07:59 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Baxter International NYSE:BAX

$19.24 -0.14 (-0.71%)

Closing price 03:59 PM Eastern

Extended Trading

$19.32 +0.07 (+0.37%)

As of 07:53 PM Eastern

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

DaVita NYSE:DVA

$191.84 -0.32 (-0.17%)

Closing price 03:59 PM Eastern

Extended Trading

$190.85 -0.99 (-0.52%)

As of 06:35 PM Eastern

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

DexCom NASDAQ:DXCM

$76.62 +3.76 (+5.16%)

Closing price 04:00 PM Eastern

Extended Trading

$75.82 -0.80 (-1.04%)

As of 07:58 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BAX, AMN, DVA, and DXCM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BAX, AMN, DVA, and DXCM Earnings

Compare Dividends

Latest BAX, AMN, DVA, and DXCM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BAX, AMN, DVA, and DXCM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BAX, AMN, DVA, and DXCM Company Descriptions

AMN Healthcare Services NYSE:AMN

Baxter International NYSE:BAX

DaVita NYSE:DVA

DexCom NASDAQ:DXCM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools